1. The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
- Author
-
Jawl-Shan Hwang, Miaw-Jene Liou, Cheng Ho, Yu-Yao Huang, Chao-Jan Wang, Keh-Sung Tsai, Jung-Fu Chen, Jen-Der Lin, Hwang, Jawl-Shan, Liou, Miaw-Jene, Ho, Cheng, Lin, Jen-Der, Huang, Yu-Yao, Wang, Chao-Jan, Tsai, Keh-Sung, and Chen, Jung-Fu
- Subjects
OSTEOPOROSIS ,BONE diseases ,BONE resorption ,BONE density ,ALKALINE phosphatase - Abstract
The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male osteoporosis in Taiwan. This 6-month, randomized, open-label controlled trial enrolled 46 men with osteoporosis who were randomized to either 70 mg alendronate once weekly (n = 23) or control (n = 23). Bone mineral density (BMD) of lumbar spine and hip and biochemical bone turnover markers were measured; adverse events and tolerability were assessed. Subjects treated with alendronate showed a significant increase in BMD of 5.5% (vs. 2% in control group) at the lumbar spine and 2.7% (vs. 0.7%) at the femoral neck (P < 0.05) at 6 months, respectively. There were also significant decreases in serum level of bone formation marker (bone-specific alkaline phosphatase) and urinary excretion of bone resorption marker (deoxypyridinoline) at 3 and 6 months. Thus, alendronate showed anti-osteoporotic effects by increasing BMD and decreasing the concentrations of bone markers. The adverse events were mild and showed no significant difference between the two groups on safety assessments. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF